Menu
Search
|

Menu

Close
X

Acer Therapeutics Inc ACER.OQ (NASDAQ Stock Exchange Capital Market)

18.73 USD
+0.09 (+0.48%)
As of 8:57 PM IST
chart
Previous Close 18.64
Open 18.99
Volume 636
3m Avg Volume 6,008
Today’s High 18.99
Today’s Low 18.73
52 Week High 21.71
52 Week Low 5.70
Shares Outstanding (mil) 0.74
Market Capitalization (mil) 12.90
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
2
FY15
3
EPS (USD)
FY17
-2.719
FY16
-11.824
FY15
-23.521
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
8.88
5.77
Price to Book (MRQ)
vs sector
8.01
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-141.39
14.43
Return on Equity (TTM)
vs sector
-141.39
16.13

EXECUTIVE LEADERSHIP

Christopher Schelling
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Harry Palmin
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Jason Kneeland
Vice President - Finance, Controller, Since 2017
Salary: --
Bonus: --
Terrie Kellmeyer
Vice President - Clinical Science, Since 2017
Salary: --
Bonus: --
John Klopp
Vice President - Manufacturing, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

One Gateway Center (300 Washingt
Suite 351
NEWTON   MA   02458

Phone: +1281.2729331

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

SPONSORED STORIES